Welcome to our dedicated page for Bicara Therapeutics SEC filings (Ticker: BCAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Bicara Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Bicara Therapeutics's regulatory disclosures and financial reporting.
Bicara Therapeutics Inc. reported that its Chief Financial Officer, Jennifer Larson, received a grant of 285,000 stock options on August 12, 2026. The options have an exercise price of $24.63 per share and are exercisable for an equal number of shares of common stock until August 12, 2036. According to the vesting terms, 25% of the options vest and become exercisable on August 12, 2027, with the remaining 75% vesting in twelve equal quarterly installments thereafter, subject to her continued service. Following this award, she holds 285,000 derivative securities of this type directly.
Bicara Therapeutics Inc. reported the initial insider ownership status of its Chief Financial Officer, Jennifer Larson, through a Form 3. The filing lists her as an officer but shows no reportable equity holdings or transactions at this time. It also references an attached Exhibit 24 granting a Power of Attorney.
Janus Henderson Group Ltd. reports beneficial ownership of Bicara Therapeutics Inc. common stock on a passive basis. Through its investment adviser subsidiaries managing various Managed Portfolios, it may be deemed to beneficially own 3,171,015 shares of common stock, representing 4.8% of the class. All voting and dispositive authority over these shares is shared among the relevant asset managers; none is held on a sole basis. Janus Henderson and its asset managers disclaim rights to receive dividends or sale proceeds, which belong to the Managed Portfolios. No individual Managed Portfolio holds more than five percent of Bicara’s common stock.
Bicara Therapeutics Inc. Chief Financial Officer Hyep Ivan exercised stock options for 12,500 shares of common stock at an exercise price of $3.7898 per share and on the same day sold 12,500 shares at a weighted average price of $27.9673 per share. The option exercise reduced the reported option position to 26,336 stock options following the transaction, with the options expiring on April 5, 2033 and vesting in sixteen equal quarterly installments following April 5, 2023. The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
Bicara Therapeutics Inc. director and Chief Executive Officer Claire Mazumdar reported option exercises and stock sales dated August 10, 2026. She exercised 10,000 stock options at an exercise price of $3.7898 per share, acquiring 10,000 shares of common stock, and then sold 10,000 common shares at a weighted average price of $27.975 per share in multiple transactions. After the exercise, she directly held 110,546 stock options linked to this grant, which expires on April 5, 2033. These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
Bicara Therapeutics Inc. President and COO Ryan Cohlhepp reported an option exercise and same‑day share sale in Bicara Therapeutics Inc. On 2026-08-10 he exercised 18,750 stock options at an exercise price of $3.7898 per share, receiving 18,750 shares of common stock. The same day, he sold 18,750 common shares at a weighted average price of $27.9751 per share, with individual sale prices ranging from $27.56 to $28.41, pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. Following the derivative transaction, 51,752 stock options remained reported outstanding, expiring on 2033-04-05, from a grant that vests in sixteen equal quarterly installments after April 5, 2023, subject to continued service.
Bicara Therapeutics Inc. is a clinical-stage oncology company focused on bifunctional antibody therapy ficerafusp alfa for solid tumors, particularly head and neck cancers. It reported a net loss of $55.4 million for the quarter and $111.6 million for the first half of 2026, reflecting heavier investment in R&D and corporate build-out.
Quarterly operating expenses rose to $60.0 million, driven by $45.8 million in research and development and $14.2 million in general and administrative costs, including higher clinical, manufacturing and stock-based compensation expenses. Cash used in operating activities was $81.7 million in the first half.
Bicara strengthened its balance sheet via a February 2026 equity and pre-funded warrant offering, bringing cash, cash equivalents and marketable securities to $497.3 million as of June 30, 2026 and total equity to $468.8 million. Management believes this capital will fund operations into the first half of 2029 while advancing the Phase 2/3 FORTIFI-HN01 pivotal trial and additional studies of ficerafusp alfa.
Bicara Therapeutics Inc. reported second quarter 2026 results and major leadership changes while advancing its lead oncology program ficerafusp alfa. Ryan Cohlhepp will become President and CEO on January 1, 2027, with current CEO Claire Mazumdar transitioning to Vice Chair of the Board and Strategic Advisor. Additional senior hires include a new CFO, Chief Business Officer and Chief Legal Officer, reflecting preparations for potential commercialization.
The company is enrolling the pivotal Phase 3 FORTIFI-HN01 trial in first-line recurrent or metastatic HPV-negative head and neck cancer and expects substantial enrollment by year-end, enabling interim topline data in mid-2027. A new FORTIFI-FLEX alternate dosing study has begun. Three-year follow-up from a Phase 1/1b cohort showed an estimated overall survival rate of 31%, approximately doubling survival seen in retrospective standard-of-care pembrolizumab data.
Financially, Bicara ended June 30, 2026 with $497.3 million in cash, cash equivalents and marketable securities and expects this to fund operations into the first half of 2029. Second quarter 2026 research and development expenses were $45.8 million and general and administrative expenses were $14.2 million, driving a net loss of $55.4 million, all higher than the prior-year period.
BCAX insider Ivan Hyep filed to sell common shares through UBS Financial Services. The notice covers 12,500 common shares with an aggregate market value of $347,875.00, expected to be sold on 08/10/2026, in connection with the exercise of stock options for cash.
The filing also lists prior sales over the past three months: 9,200 common shares for $187,883.32 on 05/21/2026 and 28,000 common shares for $807,671.05 on 07/08/2026.
BCAX affiliate Ryan Cohlhepp filed to sell up to 18,750 common shares through broker UBS Financial Services, Inc. The planned sale is tied to an Exercise of Stock Option and is scheduled for 08/10/2026 on NASDAQ, with an aggregate market value of $521,812.50.
Over the prior three months, Cohlhepp reported BCAX common stock sales of 12,500 shares for $253,648.75 on 05/15/2026, 28,214 shares for $817,584.36 on 07/08/2026, and 536 shares for $15,544.00 on 07/09/2026.